NCT02202395View on ClinicalTrials.gov

Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

December 28, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

LTS 0.25mg

use LTS 0.25mg/d

DRUG

LTS 0.5mg

use LTS 0.5mg/d

DRUG

LTS 1.0mg

use LTS 1.0mg/d

DRUG

Placebo

use placebo once daily

Trial Locations (5)

200003

Changzheng Hospital, Shanghai

200032

Zhongshan Hospital Fudan University, Shanghai

200127

Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee, Shanghai

200433

Changhai Hospital, Shanghai

233004

The first affiliated hospital of bengbu medical college, Bengbu

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

NCT02202395 - Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate | Biotech Hunter | Biotech Hunter